3Vote!
Market Wire (Free subscription) | 27/11/2009
NEW DELHI, INDIA (MARKET WIRE) US markets declined but ended off their lows on Tuesday after the Federal Reserve raised its forecast for 2010. Fed minutes indicated that Federal Reserve officials are confident the US economic recovery will be durable, but do not see employment or inflation picking up soon. Today, we, at The Fortune Financial, have asked some of the top analysts worldwide to give us...
3Vote!
San Diego Union (Free subscription) | 26/11/2009
Illumina said its board has approved a plan to buy back up to $100 million of the San Diego company’s stock. The buyback program follows a $75 million stock repurchase plan the company announced in August and has recently completed.
3Vote!
Xconomy (Free subscription) | 25/11/2009
San Diego-based Illumina (NASDAQ: ILMN) said today that its board has authorized a program to buy back $100 million of stock. The new program is on top of a $75 million share repurchase program the company announced in August.
3Vote!
Business Wire (Free subscription) | 25/11/2009
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that its Board of Directors has approved a new stock repurchase program, authorizing the company to repurchase in the aggregate up to $100 million of its outstanding common stock. The $75 million share repurchase program originally announced on August 24, 2009, recently has been completed. "Considering the strength of our...
3Vote!
Business Wire (Free subscription) | 25/11/2009
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) announced today that the company will webcast its presentation at the Piper Jaffray “Unplugged” Health Care Conference in New York, New York, on December 2, 2009. The live webcast is scheduled to begin at 11:00a.m. ET and will feature a brief overview of the company by Christian Henry, chief financial officer and senior vice president...
3Vote!
Gene Expression (Free subscription) | 23/11/2009
A a new paper in PLoS ONE , Genetic Variation and Recent Positive Selection in Worldwide Human Populations: Evidence from Nearly 1 Million SNPs : Our analyses both confirm and extend previous studies; in particular, we highlight the impact of various dispersals, and the role of substructure in Africa, on human genetic diversity. We also identified several novel candidate regions for recent positive...
3Vote!
Radon Mitigation Pittsburgh (Free subscription) | 19/11/2009
( EMAILWIRE.COM , November 19, 2009 ) Dallas, TX - Illumina, Inc. (NASDAQ:ILMN) plunged 6.65% to $29.18. The stock hit an intraday high and an intraday low of $31.19 and $28.14 respectively. In the last six months the stock went down over 20%. Illumina, Inc. is a developer, manufacturer and marketer of integrated systems for the large-scale analysis of genetic variation and biological function. The...
3Vote!
Wisconsin Technology Network (Free subscription) | 19/11/2009
EraGen Biosciences Inc., a Madison biotechnology firm, has entered into a strategic partnership and licensing agreements with San Diego-based, Illumina that will give each firm access to the other's technology. EraGen, whose products focus on detecting infectious diseases and genetic disorders, will use Illumina's analysis platforms to develop more diagnostic tests.
3Vote!
Stock Market Analysis (Free subscription) | 18/11/2009
November 18, 2009 - Below is a list of the Top 15 biggest losing stocks today that have decent volume. These stocks are usually going down on bad news. I usually throw these on my watch list and monitor them for a bounce or a potential short trade. Biggest Stock Losers - 11/18/09 1. Oncolytics Biotech, Inc. (ONCY) - News 2. Tix Corporation (TIXC) - No News 3. United Online Inc. (UNTD) - News 4. Concur...
3Vote!
MarketIntelligenceCenter.com (Free subscription) | 18/11/2009
Illumina (ILMN) appears to be trading at a higher than usual volume today and is now at $28.77, down $2.49 (-7.97%) on volume of 6,623,967 shares traded. For the last 30 days ILMN has traded 2,463,067 shares on average each day. So far today's volume is 168.93% above that average volume. Over the last 52 weeks the stock has ranged from a low of $18.82 to a high of $44.07. Illumina stock has been...
3Vote!
Business Wire (Free subscription) | 18/11/2009
MADISON, Wis.--(BUSINESS WIRE)--EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc., a global company that develops, manufactures and markets integrated systems for analysis of genetic variation and biological function, today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements....
3Vote!
PR News Wire (Free subscription) | 18/11/2009
CHICAGO, Nov. 18 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for V, SLB, CELG, ILMN, and AWK.
3Vote!
GuruFocus Updates (Free subscription) | 17/11/2009
By insider. President & CEO of Illumina Inc. ( ILMN ) Jay T Flatley sells 25,000 shares of ILMN on 11/12/2009 at an average price of $33 a share. Read more » »
3Vote!
GuruFocus Updates (Free subscription) | 13/11/2009
By insider. Sr VP & CFO of Illumina Inc. ( ILMN ) Christian O Henry sells 4,500 shares of ILMN on 11/09/2009 at an average price of $32.82 a share. Read more » »
3Vote!
PLoS ONE (Free subscription) | 07/11/2009
Cancer patients show large individual variation in their response to chemotherapeutic agents. Gemcitabine (dFdC) and AraC, two cytidine analogues, have shown significant activity against a variety of tumors. We previously used expression data from a lymphoblastoid cell line-based model system to identify genes that might be important for the two drug cytotoxicity. In the present study, we used that...
Videos